Sci Rep:不同放射治疗在局部前列腺癌患者中的比较

2018-07-24 AlexYang MedSci原创

最近,有研究人员为了比较低剂量短距离放射治疗(LDR-BT)和图像指导强度的放射治疗(IG-IMRT)在局部前列腺癌中的治疗效果,他们调查了488名LDR-BT患者和269名IG-IMRT患者。研究发现,IG-IMRT用于治疗更加年老的和晚期的疾病,并且激素治疗要比LDR-BT多,其中不包括T3b-T4肿瘤和起始PSA>50ng/ml的患者。IG-IMRT和LDR-BT中实际的5年无生化失败

最近,有研究人员为了比较低剂量短距离放射治疗(LDR-BT)和图像指导强度的放射治疗(IG-IMRT)在局部前列腺癌中的治疗效果,他们调查了488名LDR-BT患者和269名IG-IMRT患者。

研究发现,IG-IMRT用于治疗更加年老的和晚期的疾病,并且激素治疗要比LDR-BT多,其中不包括T3b-T4肿瘤和起始PSA>50ng/ml的患者。IG-IMRT和LDR-BT中实际的5年无生化失败生存率分别为88.7%和96.7%(p=0.0003);其中高风险组为88.2%(IG-IMRT为85.1% ,LDR-BT为 94.9% , p=0.0578),中等程度IG-IMRT为95.2%(91.6%和97.0%, p=0.3361),低风险组为96.8%(95.7% 和97%, p=0.8625)。另外,与倾向性得分有关的治疗权重逆概率(IPTW)被用来减少背景选择偏差。研究发现,高风险组(p=0.0009)和不包括T3-T4肿瘤和起始PSA>50ng/ml组(p=0.0073)中,IPTW在LDT-BT和IG-IMTR展现出了统计学显著的差异。与LDR-BT相比,IG-IMRT表现出了更强的胃肠道毒性(p=0.0023)和更少的泌尿道生殖毒性(p<0.0001)。

最后,研究人员指出,LDR-BT和IG-IMRT在低风险和中等风险组中表现出了不明确的治疗结果。但对于选择的高风险患者,LDR-BT表现出了比IG-IMRT更好的改善PSA控制率的能力。.

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046240, encodeId=4a1f204624047, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Nov 18 03:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334301, encodeId=dd91334301d7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 26 12:50:03 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405847, encodeId=ea3d140584ed2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jul 26 10:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333993, encodeId=175b3339933a, content=学术性太强了,只能了解一下。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Wed Jul 25 06:59:13 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333901, encodeId=aeb633390114, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Jul 24 20:10:06 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046240, encodeId=4a1f204624047, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Nov 18 03:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334301, encodeId=dd91334301d7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 26 12:50:03 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405847, encodeId=ea3d140584ed2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jul 26 10:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333993, encodeId=175b3339933a, content=学术性太强了,只能了解一下。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Wed Jul 25 06:59:13 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333901, encodeId=aeb633390114, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Jul 24 20:10:06 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
    2018-07-26 一个字-牛

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2046240, encodeId=4a1f204624047, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Nov 18 03:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334301, encodeId=dd91334301d7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 26 12:50:03 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405847, encodeId=ea3d140584ed2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jul 26 10:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333993, encodeId=175b3339933a, content=学术性太强了,只能了解一下。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Wed Jul 25 06:59:13 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333901, encodeId=aeb633390114, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Jul 24 20:10:06 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
    2018-07-26 chg122
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046240, encodeId=4a1f204624047, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Nov 18 03:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334301, encodeId=dd91334301d7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 26 12:50:03 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405847, encodeId=ea3d140584ed2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jul 26 10:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333993, encodeId=175b3339933a, content=学术性太强了,只能了解一下。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Wed Jul 25 06:59:13 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333901, encodeId=aeb633390114, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Jul 24 20:10:06 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
    2018-07-25 邓启付

    学术性太强了,只能了解一下。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2046240, encodeId=4a1f204624047, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Nov 18 03:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334301, encodeId=dd91334301d7, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 26 12:50:03 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405847, encodeId=ea3d140584ed2, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Thu Jul 26 10:54:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333993, encodeId=175b3339933a, content=学术性太强了,只能了解一下。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Wed Jul 25 06:59:13 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333901, encodeId=aeb633390114, content=好文章,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Jul 24 20:10:06 CST 2018, time=2018-07-24, status=1, ipAttribution=)]
    2018-07-24 1e0f8808m18(暂无匿称)

    好文章,学习了。

    0

相关资讯

Cell:重大进展,前列腺癌基因组上的深层次突破

虽然已经在许多癌症中检查了影响蛋白质编码区的突变,但是对于前列腺癌在全基因组水平上的结构变体仍然定义不明确。2018年7月19日,加利福尼亚大学旧金山分校Feng等研究组合作在Cell在线发表题为“Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer”研究论文,该论文通过对101种去势抵抗性前列腺癌转移(1

Prostate Cancer P D:MRI靶向生物活检不能够准确定位在系统性活检中发现的前列腺癌

磁共振成像(MRI)/超声融合(US)指导的活检已经具有更好的定位和检测前列腺癌(PCa)的能力,并且效率要胜过系统性活检。尽管如此,一些患有PCa的患者在利用MRI靶向活检单独检测时仍旧被错过。最近,有研究人员在靶向活检错过的案例中鉴定了相关的临床的和成像参数。研究发现,35/127(27.6%)名利用单次MRI/US融合指导的活检加上标准活检发现的PCa具有病灶不正确定位的现象。在这些患者中,

Sci Rep:利用Gd标签的红细胞产生的多参数MRI图谱来阐释前列腺癌的表型和阶段

前列腺癌(PCa)在西方国家中是第二大最常见的癌症,也是男性癌症相关致死的第5大死因。早期、更加精确的和非侵入性的创新性诊断工具的开发在医学上时迫切需要的。血管容积(Vv)和组织缺氧是2中最常见的重要肿瘤标志。因此,最近,有研究人员利用MRI技术在TRAMP小鼠中对上述2中标志进行了评估,并利用体外标记Gd-HPDO3A 或者Gd-DOTP的自体同源红细胞(RBCs)复合物分别进行注射来对上述2中

盘点:前列腺癌治疗研究盘点

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Cancer Causes Control:进行局部前列腺癌雄激素阻

Brit J Cancer:雄激素受体剪接变异AR-V3, AR-V7和AR-V9在去势难治性前列腺癌转移中是持续共表达的

前列腺癌(PC)患者中的一部分去势难治性前列腺(CRPC)患者表现出对雄激素受体(AR)靶向药物的原发抗性。其中的一个解释是持续的活性性激素受体剪接本变异(AR-Vs)的表达,最近,有研究人员探究了AR-Vs和其他AR畸变产物,从而更好的理解CRPC的产生。研究人员利用二代测序和免疫组化染色技术分析了不同阶段前列腺癌患者的样本。研究发现,旨在CRPC样本中检测到了AR变异和拷贝数的变化,且在5/3

盘点:前列腺癌进展盘点

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Nat Genet:大数据!对14万男性的相关分析鉴定了63个新的前